ZEAL Overview
Upcoming Projects (ZEAL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ZEAL)
-
A Third Look: Getting a physicians thoughts on Zealand Pharmaceuticals Phase 1b, 13 week data on Dapiglutide
Ticker: ZEAL
Executed On: Sep 19, 2024 at 12:15 PM EDT -
A Second Look: Getting a physicians thoughts on Zealand Pharmaceuticals Phase 1b, 13 week data on Dapiglutide
Ticker: ZEAL
Executed On: Sep 19, 2024 at 11:45 AM EDT -
Getting a physicians thoughts on Zealand Pharmaceuticals Phase 1b, 13 week data on Dapiglutide
Ticker: ZEAL
Executed On: Sep 19, 2024 at 11:05 AM EDT -
A Third Opinion: An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jul 25, 2024 at 01:00 PM EDT -
A Second Opinion: An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jul 24, 2024 at 03:00 PM EDT -
A Third Opinion: Looking at Zealand Pharmaceuticals Phase 1b, 16 week data on Petrelintide for weight loss
Ticker: ZEAL
Executed On: Jun 28, 2024 at 04:00 PM EDT -
A Second Opinion: Looking at Zealand Pharmaceuticals Phase 1b, 16 week data on Petrelintide for weight loss
Ticker: ZEAL
Executed On: Jun 28, 2024 at 01:15 PM EDT -
Looking at Zealand Pharmaceuticals Phase 1b, 16 week data on Petrelintide for weight loss
Ticker: ZEAL
Executed On: Jun 28, 2024 at 10:00 AM EDT -
An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jun 25, 2024 at 04:00 PM EDT -
A Third View: Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: Aug 08, 2023 at 04:15 PM EDT -
A Second View: Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: Aug 04, 2023 at 05:00 PM EDT -
Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: Aug 03, 2023 at 11:00 AM EDT -
Discussing the standard of care and the potential of Boehringer Ingelheim's BI 456906, a novel glucagon/GLP-1 receptor dual agonist, once-weekly injectable to treat obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: May 17, 2023 at 05:30 PM EDT
Upcoming & Overdue Catalysts (ZEAL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ZEAL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
